Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Phase of Trial: Phase I/II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs RG 4733 (Primary) ; Bevacizumab
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 11 Dec 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 13 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.